Helius Medical initiated with a Buy at BTIG
BTIG analyst Sean Lavin initiated Helius Medical with a Buy rating and a price target of $14, saying the company's offerings have the "potential to help people with traumatic brain injuries to regain normal function, balance, and the ability to walk." Lavin adds that Helius Medical's Portable Neuromodulation Stimulator is shown to produce "significant improvement in balance and function" in patients, who have "no other good options", expecting the company to target workers' comp, the military, and normal medical insurers. He also expects the investment story to result in positive public sentiment, driving adoption and reimbursement. The analyst does note some risks for the company, including its recently missed primary efficacy endpoint. which could prompt the FDA to ask for more data. as well as the company's impending capital needs.